{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:54:22Z","timestamp":1781243662573,"version":"3.54.1"},"reference-count":230,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>One of the utmost frequently emerging neurodegenerative diseases, Parkinson\u2019s disease (PD) must be comprehended through the forfeit of dopamine (DA)-generating nerve cells in the substantia nigra pars compacta (SN-PC). The etiology and pathogenesis underlying the emergence of PD is still obscure. However, expanding corroboration encourages the involvement of genetic and environmental factors in the etiology of PD. The destruction of numerous cellular components, namely oxidative stress, ubiquitin-proteasome system (UPS) dysfunction, autophagy-lysosome system dysfunction, neuroinflammation and programmed cell death, and mitochondrial dysfunction partake in the pathogenesis of PD. Present-day pharmacotherapy can alleviate the manifestations, but no therapy has been demonstrated to cease disease progression. Peroxisome proliferator-activated receptors (PPARs) are ligand-directed transcription factors pertaining to the class of nuclear hormone receptors (NHR), and are implicated in the modulation of mitochondrial operation, inflammation, wound healing, redox equilibrium, and metabolism of blood sugar and lipids. Numerous PPAR agonists have been recognized to safeguard nerve cells from oxidative destruction, inflammation, and programmed cell death in PD and other neurodegenerative diseases. Additionally, various investigations suggest that regular administration of PPAR-activating non-steroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, indomethacin), and leukotriene receptor antagonists (montelukast) were related to the de-escalated evolution of neurodegenerative diseases. The present review elucidates the emerging evidence enlightening the neuroprotective outcomes of PPAR agonists in in vivo and in vitro models experiencing PD. Existing articles up to the present were procured through PubMed, MEDLINE, etc., utilizing specific keywords spotlighted in this review. Furthermore, the authors aim to provide insight into the neuroprotective actions of PPAR agonists by outlining the pharmacological mechanism. As a conclusion, PPAR agonists exhibit neuroprotection through modulating the expression of a group of genes implicated in cellular survival pathways, and may be a propitious target in the therapy of incapacitating neurodegenerative diseases like PD.<\/jats:p>","DOI":"10.3390\/ijms221810161","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T08:04:23Z","timestamp":1632211463000},"page":"10161","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Elucidating the Neuroprotective Role of PPARs in Parkinson\u2019s Disease: A Neoteric and Prospective Target"],"prefix":"10.3390","volume":"22","author":[{"given":"Tapan","family":"Behl","sequence":"first","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6001-125X","authenticated-orcid":false,"given":"Piyush","family":"Madaan","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayush","family":"Sehgal","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhbir","family":"Singh","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Sharma","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Natural & Medical Sciences Research Centre, University of Nizwa, Birkat Al Mauz 616, Nizwa P.O. Box 33, Oman"},{"name":"School of Health Science, University of Petroleum and Energy Studies, Dehradun 248007, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0815-5942","authenticated-orcid":false,"given":"Ahmed","family":"Al-Harrasi","sequence":"additional","affiliation":[{"name":"Natural & Medical Sciences Research Centre, University of Nizwa, Birkat Al Mauz 616, Nizwa P.O. Box 33, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-2964","authenticated-orcid":false,"given":"Sridevi","family":"Chigurupati","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraydah 52571, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Alrashdi","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne NE1 7RU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-1292","authenticated-orcid":false,"given":"Simona Gabriela","family":"Bungau","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania"},{"name":"Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/NHH.0000000000000398","article-title":"Parkinson Disease","volume":"34","author":"Capriotti","year":"2016","journal-title":"Home Healthc. Now"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","article-title":"Parkinson\u2019s Disease and Parkinsonism","volume":"132","author":"Hayes","year":"2019","journal-title":"Am J Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"124","author":"Tysnes","year":"2017","journal-title":"J. Neural Transm"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00415-016-8384-9","article-title":"The relevance of gender in Parkinson\u2019s disease: A review","volume":"264","author":"Picillo","year":"2017","journal-title":"J. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1146\/annurev-neuro-100720-034518","article-title":"Parkinson\u2019s Disease Genetics and Pathophysiology","volume":"44","author":"Zoghbi","year":"2021","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejphar.2015.01.030","article-title":"Management of Parkinson\u05f3s disease: Current and future pharmacotherapy","volume":"750","author":"Kakkar","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.2174\/0929867327666200716113136","article-title":"Role of Peroxisome Proliferator-Activated Receptor Gamma (PPAR\u03b3) in Different Disease States: Recent Updates","volume":"28","author":"Mal","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s12640-020-00323-9","article-title":"Peroxisomes of the Brain: Distribution, Functions, and Associated Diseases","volume":"39","author":"Deb","year":"2021","journal-title":"Neurotox Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.4103\/1673-5374.297072","article-title":"Nuclear peroxisome proliferator activated receptor-gamma (PPAR\u03b3) as a therapeutic target to treat neurodegeneration and dependence elicited by drugs of abuse","volume":"16","author":"Ciccocioppo","year":"2021","journal-title":"Neural Regen. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.52711\/0974-360X.2021.00688","article-title":"A Mechanistic approach of Peroxisome Proliferator-Activated Receptors and its subtypes on Clinical and preclinical model of Neurodegenerative disorders","volume":"14","author":"Avarachan","year":"2021","journal-title":"Res. J. Pharm. Technol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/03602532.2021.1903488","article-title":"Ibuprofen-based advanced therapeutics: Breaking the inflammatory link in cancer, neurodegeneration, and diseases","volume":"53","author":"Upadhyay","year":"2021","journal-title":"Drug Metab. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12974-018-1179-4","article-title":"Indomethacin promotes survival of new neurons in the adult murine hippocampus accompanied by anti-inflammatory effects following MPTP-induced dopamine depletion","volume":"15","author":"Hain","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Michael, J., Zirknitzer, J., Unger, M.S., Poupardin, R., Rie\u00df, T., Paiement, N., Zerbe, H., Hutter-Paier, B., Reitsamer, H., and Aigner, L. (2021). The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5 \u00d7 FAD Mice. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052782"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mahalakshmi, B., Maurya, N., Lee, S.-D., and Bharath Kumar, V. (2020). Possible Neuroprotective Mechanisms of Physical Exercise in Neurodegeneration. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165895"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","article-title":"The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases","volume":"2","author":"Tyagi","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"ref_16","first-page":"649","article-title":"Peroxisome proliferator-activated receptors: Nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocr. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.2174\/092986705774462905","article-title":"PPARs in diseases: Control mechanisms of inflammation","volume":"12","author":"Kostadinova","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.freeradbiomed.2016.06.023","article-title":"PPAR\u03b3 as a therapeutic target to rescue mitochondrial function in neurological disease","volume":"100","author":"Corona","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s11064-014-1377-0","article-title":"PPAR\u03b3 and PGC-1\u03b1 as therapeutic targets in Parkinson\u2019s","volume":"40","author":"Corona","year":"2015","journal-title":"Neurochem. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12035-012-8259-8","article-title":"Peroxisome proliferator-activated receptor gamma (PPAR-\u03b3) and neurodegenerative disorders","volume":"46","author":"Chen","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/sj.ijo.0802905","article-title":"Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-\u03b1","volume":"29","author":"Puigserver","year":"2005","journal-title":"Int. J. Obes."},{"key":"ref_22","first-page":"29275","article-title":"RAR\/RXR and PPAR\/RXR signaling in spinal cord injury","volume":"2007","author":"Mey","year":"2007","journal-title":"PPAR Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bbalip.2007.01.007","article-title":"Peroxisome proliferator-activated receptor structures: Ligand specificity, molecular switch and interactions with regulators","volume":"1771","author":"Zoete","year":"2007","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1385\/CBB:32:1-3:187","article-title":"Peroxisome proliferator-activated receptors, coactivators, and downstream targets","volume":"32","author":"Qi","year":"2000","journal-title":"Cell Biochem. Biophys."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.febslet.2007.11.081","article-title":"Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR\u2013RXR complex","volume":"582","author":"Ziouzenkova","year":"2008","journal-title":"FEBS Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.it.2007.09.003","article-title":"Anti-inflammatory actions of PPAR ligands: New insights on cellular and molecular mechanisms","volume":"28","author":"Straus","year":"2007","journal-title":"Trends Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1074\/jbc.272.6.3406","article-title":"Peroxisome proliferator-activated receptors \u03b1 and \u03b3 are activated by indomethacin and other non-steroidal anti-inflammatory drugs","volume":"272","author":"Lehmann","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0006-2952(01)00822-X","article-title":"Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H2 synthases by ibuprofen, naproxen, and indomethacin","volume":"62","author":"Jaradat","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2015.11.004","article-title":"Fatty acids, eicosanoids and PPAR gamma","volume":"785","author":"Savoye","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"25038","DOI":"10.1074\/jbc.M112.374041","article-title":"Lipolytic products activate peroxisome proliferator-activated receptor (PPAR) \u03b1 and \u03b4 in brown adipocytes to match fatty acid oxidation with supply","volume":"287","author":"Mottillo","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.bbrc.2016.08.043","article-title":"Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders","volume":"483","author":"Agarwal","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.dsx.2014.09.015","article-title":"PPAR gamma gene\u2013a review","volume":"9","author":"Janani","year":"2015","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.arr.2008.01.001","article-title":"Molecular mechanism of PPAR in the regulation of age-related inflammation","volume":"7","author":"Chung","year":"2008","journal-title":"Ageing Res. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.tem.2006.08.005","article-title":"Nuclear receptors versus inflammation: Mechanisms of transrepression","volume":"17","author":"Pascual","year":"2006","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1042\/bse0470069","article-title":"Regulation of mitochondrial biogenesis","volume":"47","author":"Brown","year":"2010","journal-title":"Essays Biochem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.2337\/diabetes.54.5.1392","article-title":"Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo","volume":"54","author":"Bogacka","year":"2005","journal-title":"Diabetes"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1124\/mol.106.033845","article-title":"The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells","volume":"71","author":"Ghosh","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1074\/jbc.M208132200","article-title":"Peroxisome proliferator-activated receptor \u03b3 thiazolidinedione agonists increase glucose metabolism in astrocytes","volume":"278","author":"Russo","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.drudis.2014.05.001","article-title":"mitoNEET as a novel drug target for mitochondrial dysfunction","volume":"19","author":"Geldenhuys","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"14342","DOI":"10.1073\/pnas.0707189104","article-title":"MitoNEET is a uniquely folded 2Fe\u20132S outer mitochondrial membrane protein stabilized by pioglitazone","volume":"104","author":"Paddock","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/JAD-2007-11108","article-title":"Rosiglitazone induces mitochondrial biogenesis in mouse brain","volume":"11","author":"Strum","year":"2007","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"31781","DOI":"10.1074\/jbc.M204279200","article-title":"Thiazolidinedione activation of peroxisome proliferator-activated receptor \u03b3 can enhance mitochondrial potential and promote cell survival","volume":"277","author":"Wang","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev.nutr.21.1.193","article-title":"Peroxisomal \u03b2-oxidation and peroxisome proliferator\u2013activated receptor \u03b1: An adaptive metabolic system","volume":"21","author":"Reddy","year":"2001","journal-title":"Annu. Rev. Nutr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/nm1672","article-title":"PPAR-\u03b3 regulates osteoclastogenesis in mice","volume":"13","author":"Wan","year":"2007","journal-title":"Nat. Med."},{"key":"ref_45","first-page":"649","article-title":"Effects of rosiglitazone on Kruppul-like factor 6 (KLF6) signaling in the livers of rats with nonalcoholic fatty liver fibrosis","volume":"15","author":"Wang","year":"2007","journal-title":"Zhonghua Gan Zang Bing Za Zhi\/Zhonghua Ganzangbing Zazhi\/Chin. J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11064-006-9138-3","article-title":"Effects of thiazolidinediones on stroke recovery: A case-matched controlled study","volume":"32","author":"Lee","year":"2007","journal-title":"Neurochem. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"60704","DOI":"10.18632\/oncotarget.19610","article-title":"Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy","volume":"8","author":"Gou","year":"2017","journal-title":"Oncotarget"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/CAD.0b013e328011e67d","article-title":"Peroxisome proliferator-activated receptor \u03b3: A novel target for cancer therapeutics?","volume":"18","author":"Han","year":"2007","journal-title":"Anti-Cancer Drugs"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Khuchua, Z., Glukhov, A.I., Strauss, A.W., and Javadov, S. (2018). Elucidating the beneficial role of PPAR agonists in cardiac diseases. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113464"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.beem.2007.09.004","article-title":"PPAR agonists: Multimodal drugs for the treatment of type-2 diabetes","volume":"21","author":"Gross","year":"2007","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.bbalip.2007.04.016","article-title":"PPARs in the brain","volume":"1771","author":"Heneka","year":"2007","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1471-4159.2006.04376.x","article-title":"Peroxisome proliferator-activated receptor-\u03b3 agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents","volume":"101","author":"Tureyen","year":"2007","journal-title":"J. Neurochem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1471-4159.2006.03758.x","article-title":"Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-\u03b3 agonist rosiglitazone","volume":"97","author":"Luo","year":"2006","journal-title":"J. Neurochem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"37006","DOI":"10.1074\/jbc.M700447200","article-title":"Peroxisome proliferator-activated receptor \u03b3 up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis","volume":"282","author":"Fuenzalida","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1124\/jpet.106.113472","article-title":"Thiazolidinedione class of peroxisome proliferator-activated receptor \u03b3 agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats","volume":"320","author":"Park","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.expneurol.2007.02.009","article-title":"The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury","volume":"205","author":"McTigue","year":"2007","journal-title":"Exp. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"10908","DOI":"10.1523\/JNEUROSCI.3987-04.2004","article-title":"Peroxisome proliferator-activated receptor \u03b3 induces a clearance mechanism for the amyloid-\u03b2 peptide","volume":"24","author":"Camacho","year":"2004","journal-title":"J. Neurosci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1471-4159.2008.05388.x","article-title":"PPAR: A therapeutic target in Parkinson\u2019s disease","volume":"106","author":"Chaturvedi","year":"2008","journal-title":"J. Neurochem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s11064-020-02993-5","article-title":"The novel role of PPAR alpha in the brain: Promising target in therapy of Alzheimer\u2019s disease and other neurodegenerative disorders","volume":"45","author":"Strosznajder","year":"2020","journal-title":"Neurochem. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"418765","DOI":"10.1155\/2008\/418765","article-title":"Peroxisome Proliferator-Activated Receptor-in Amyotrophic Lateral Sclerosis and Huntington\u2019s Disease","volume":"2008","author":"Kiaei","year":"2008","journal-title":"PPAR Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1517\/14728220802515400","article-title":"Targeting PPAR as a therapy to treat multiple sclerosis","volume":"12","author":"Bright","year":"2008","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Lee, T., and Yankee, E. (2021). A review on Parkinson\u2019s disease treatment. Neuroimmunol. Neuroinflamm., 8.","DOI":"10.20517\/2347-8659.2020.58"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.neuron.2019.03.004","article-title":"Circuit mechanisms of Parkinson\u2019s disease","volume":"101","author":"McGregor","year":"2019","journal-title":"Neuron"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3389\/fphar.2020.00356","article-title":"Modeling Parkinson\u2019s disease with the alpha-synuclein protein","volume":"11","author":"Granado","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Xu, L., and Pu, J. (2016). Alpha-synuclein in Parkinson\u2019s disease: From pathogenetic dysfunction to potential clinical application. Parkinson\u2019s Dis., 2016.","DOI":"10.1155\/2016\/1720621"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"V\u00e1radi, C. (2020). Clinical features of Parkinson\u2019s disease: The evolution of critical symptoms. Biology, 9.","DOI":"10.3390\/biology9050103"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1159\/000445751","article-title":"The incidence of Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"46","author":"Hirsch","year":"2016","journal-title":"Neuroepidemiology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1212\/01.wnl.0000341769.50075.bb","article-title":"Incidence and remaining lifetime risk of Parkinson disease in advanced age","volume":"72","author":"Driver","year":"2009","journal-title":"Neurology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JPD-191683","article-title":"Parkinson\u2019s disease in women and men: What\u2019s the difference?","volume":"9","author":"Cerri","year":"2019","journal-title":"J. Parkinson\u2019s Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20017","article-title":"UCHL1 is a Parkinson\u2019s disease susceptibility gene","volume":"55","author":"Maraganore","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep24475","article-title":"The Parkinson Disease gene SNCA: Evolutionary and structural insights with pathological implication","volume":"6","author":"Siddiqui","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.2174\/1570159X16666180222165418","article-title":"The role of LRRK2 in neurodegeneration of Parkinson disease","volume":"16","author":"Rui","year":"2018","journal-title":"Curr. Neuropharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-020-01062-w","article-title":"PINK1\/PARKIN signalling in neurodegeneration and neuroinflammation","volume":"8","author":"Quinn","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Repici, M., and Giorgini, F. (2019). DJ-1 in Parkinson\u2019s disease: Clinical insights and therapeutic perspectives. J. Clin. Med., 8.","DOI":"10.3390\/jcm8091377"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3233\/JPD-171092","article-title":"Glucocerebrosidase mutations in Parkinson disease","volume":"7","author":"DeSouza","year":"2017","journal-title":"J. Parkinson\u2019s Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1289\/ehp.1002839","article-title":"Rotenone, paraquat, and Parkinson\u2019s disease","volume":"119","author":"Tanner","year":"2011","journal-title":"Environ. Health Perspect."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.taap.2012.11.016","article-title":"Solvents and Parkinson disease: A systematic review of toxicological and epidemiological evidence","volume":"266","author":"Lock","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1212\/WNL.0000000000001362","article-title":"Head injury and risk for Parkinson disease: Results from a Danish case-control study","volume":"84","author":"Kenborg","year":"2015","journal-title":"Neurology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e869","DOI":"10.1097\/MD.0000000000000869","article-title":"Increased risk of Parkinson disease in patients with carbon monoxide intoxication: A population-based cohort study","volume":"94","author":"Lai","year":"2015","journal-title":"Medicine"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/JNN.0000000000000162","article-title":"Understanding Parkinson disease: A complex and multifaceted illness","volume":"47","author":"Gopalakrishna","year":"2015","journal-title":"J. Neurosci. Nurs."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.metabol.2008.07.015","article-title":"Parkinson disease: Primacy of age as a risk factor for mitochondrial dysfunction","volume":"57","author":"VanItallie","year":"2008","journal-title":"Metabolism"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1212\/WNL.45.12.2143","article-title":"Prevalence of Parkinson\u2019s disease in the elderly: The Rotterdam Study","volume":"45","author":"Breteler","year":"1995","journal-title":"Neurology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1212\/WNL.52.6.1214","article-title":"Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976\u20131990","volume":"52","author":"Bower","year":"1999","journal-title":"Neurology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"410","DOI":"10.5694\/mja17.01074","article-title":"Impact of ethnicity on the natural history of Parkinson disease","volume":"208","author":"Sauerbier","year":"2018","journal-title":"Med. J. Aust."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.arr.2017.12.007","article-title":"The genetics of Parkinson disease","volume":"42","author":"Deng","year":"2018","journal-title":"Ageing Res. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2174\/1389203717666160217143721","article-title":"Familial mutations and post-translational modifications of UCH-L1 in Parkinson\u2019s disease and neurodegenerative disorders","volume":"18","year":"2017","journal-title":"Curr. Protein Pept. Sci."},{"key":"ref_88","first-page":"201","article-title":"Expression of \u03b1-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: Genes associated with familial Parkinson\u2019s disease","volume":"47","author":"Solano","year":"2000","journal-title":"Ann. Neurol. Off. J. Am. Neurol. Assoc. Child. Neurol. Soc."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0022-510X(81)90032-0","article-title":"The demonstration of new human brain-specific proteins by high-resolution two-dimensional polyacrylamide gel electrophoresis","volume":"49","author":"Jackson","year":"1981","journal-title":"J. Neurol. Sci."},{"key":"ref_90","first-page":"S73","article-title":"Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson\u2019s disease","volume":"53","author":"McNaught","year":"2003","journal-title":"Ann. Neurol. Off. J. Am. Neurol. Assoc. Child. Neurol. Soc."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/nrn1788","article-title":"Axon degeneration mechanisms: Commonality amid diversity","volume":"6","author":"Coleman","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/12647","article-title":"Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice","volume":"23","author":"Saigoh","year":"1999","journal-title":"Nat. Genet."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1471-4159.2004.02485.x","article-title":"UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson\u2019s disease","volume":"90","author":"Ardley","year":"2004","journal-title":"J. Neurochem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1096\/fj.03-0338rev","article-title":"\u03b1-Synuclein and Parkinson\u2019s disease","volume":"18","author":"Recchia","year":"2004","journal-title":"FASEB J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/humu.21277","article-title":"Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update","volume":"31","author":"Nuytemans","year":"2010","journal-title":"Hum. Mutat."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"18676","DOI":"10.1073\/pnas.0508052102","article-title":"Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration","volume":"102","author":"Smith","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1093\/hmg\/ddp012","article-title":"Parkinson\u2019s disease: From monogenic forms to genetic susceptibility factors","volume":"18","author":"Lesage","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/jnr.21949","article-title":"Leucine-rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson\u2019s disease","volume":"87","author":"Gandhi","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/humu.20507","article-title":"Pathogenic mutations in Parkinson disease","volume":"28","author":"Tan","year":"2007","journal-title":"Hum. Mutat."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Hilker, R., Pilatus, U., Eggers, C., Hagenah, J., Roggendorf, J., Baudrexel, S., Klein, J.C., Neumaier, B., Fink, G.R., and Steinmetz, H. (2012). The bioenergetic status relates to dopamine neuron loss in familial PD with PINK1 mutations. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0051308"},{"key":"ref_101","first-page":"1","article-title":"Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models","volume":"6","author":"Beavan","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_102","first-page":"e1036","article-title":"Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease","volume":"96","author":"Dalen","year":"2021","journal-title":"Neurology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/acn3.177","article-title":"Progressive decline of glucocerebrosidase in aging and P arkinson\u2019s disease","volume":"2","author":"Rocha","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/brain\/awt367","article-title":"Reduced glucocerebrosidase is associated with increased \u03b1-synuclein in sporadic Parkinson\u2019s disease","volume":"137","author":"Murphy","year":"2014","journal-title":"Brain"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pneurobio.2014.12.001","article-title":"Gaucher-related synucleinopathies: The examination of sporadic neurodegeneration from a rare (disease) angle","volume":"125","author":"Sardi","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1074\/jbc.M112.402123","article-title":"Metabolism of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: Implications in Parkinson disease","volume":"288","author":"Bajpai","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_107","first-page":"422","article-title":"MPTP-induced mouse model of Parkinson\u2019s disease: A promising direction for therapeutic strategies","volume":"21","author":"Mustapha","year":"2021","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Behl, T., Kaur, G., Sehgal, A., Bhardwaj, S., Singh, S., Buhas, C., Judea-Pusta, C., Uivarosan, D., Munteanu, M.A., and Bungau, S. (2021). Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031413"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.21717","article-title":"Professional exposure to pesticides and Parkinson disease","volume":"66","author":"Elbaz","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3109\/10408444.2012.680431","article-title":"Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson\u2019s disease models","volume":"42","author":"Xiong","year":"2012","journal-title":"Crit. Rev. Toxicol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0006-291X(86)91210-6","article-title":"Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity","volume":"137","author":"Sandy","year":"1986","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"30528","DOI":"10.1007\/s11356-021-14127-7","article-title":"Expatiating the impact of anthropogenic aspects and climatic factors on long-term soil monitoring and management","volume":"28","author":"Bungau","year":"2021","journal-title":"Environ. Sci. Pollut. Res."},{"key":"ref_113","first-page":"1","article-title":"Parkinson\u2019s disease (the life cycle of the dopamine neuron)","volume":"991","author":"Federoff","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_114","first-page":"1","article-title":"Meta-analysis of brain iron levels of Parkinson\u2019s disease patients determined by postmortem and MRI measurements","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Aoyama, K. (2021). Glutathione in the Brain. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22095010"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fnmol.2018.00236","article-title":"Oxidative stress in Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"11","author":"Wei","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00401-004-0937-9","article-title":"Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson\u2019s disease and related neurodegenerative disorders","volume":"109","author":"Fukae","year":"2005","journal-title":"Acta Neuropathol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0002-9440(10)65396-5","article-title":"Parkinson\u2019s disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons","volume":"154","author":"Zhang","year":"1999","journal-title":"Am. J. Pathol."},{"key":"ref_119","first-page":"2360872","article-title":"Oxidative stress in parkinson\u2019s disease: Potential benefits of antioxidant supplementation","volume":"2020","author":"Varela","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Subedi, L., Gaire, B.P., Kim, S.-Y., and Parveen, A. (2021). Nitric Oxide as a Target for Phytochemicals in Anti-Neuroinflammatory Prevention Therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094771"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"10810","DOI":"10.1073\/pnas.0404161101","article-title":"Nitrosative stress linked to sporadic Parkinson\u2019s disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity","volume":"101","author":"Yao","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.niox.2006.07.003","article-title":"Nitric oxide synthase regulation and diversity: Implications in Parkinson\u2019s disease","volume":"15","author":"Kavya","year":"2006","journal-title":"Nitric Oxide"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.neurobiolaging.2016.11.008","article-title":"Aldose reductase deficiency leads to oxidative stress-induced dopaminergic neuronal loss and autophagic abnormality in an animal model of Parkinson\u2019s disease","volume":"50","author":"Yeung","year":"2017","journal-title":"Neurobiol Aging."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Rathnayake, D., Chang, T., and Udagama, P. (2019). Selected serum cytokines and nitric oxide as potential multi-marker biosignature panels for Parkinson disease of varying durations: A case-control study. BMC Neurol., 19.","DOI":"10.1186\/s12883-019-1286-6"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","article-title":"Neuroinflammation in Parkinson\u2019s disease: A target for neuroprotection?","volume":"8","author":"Hirsch","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1089\/ars.2013.5802","article-title":"The ubiquitin-proteasome system in neurodegeneration","volume":"21","author":"McKinnon","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0304-3940(00)01701-8","article-title":"Proteasomal function is impaired in substantia nigra in Parkinson\u2019s disease","volume":"297","author":"McNaught","year":"2001","journal-title":"Neurosci. Lett."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2174\/156720510792231766","article-title":"Ubiquitin enzymes, ubiquitin and proteasome activity in blood mononuclear cells of MCI, Alzheimer and Parkinson patients","volume":"7","author":"Ullrich","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1006\/exnr.2002.8050","article-title":"Altered proteasomal function in sporadic Parkinson\u2019s disease","volume":"179","author":"McNaught","year":"2003","journal-title":"Exp. Neurol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0304-3940(02)00296-3","article-title":"Selective loss of 20S proteasome \u03b1-subunits in the substantia nigra pars compacta in Parkinson\u2019s disease","volume":"326","author":"McNaught","year":"2002","journal-title":"Neurosci. Lett."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1172\/JCI200317575","article-title":"Rare genetic mutations shed light on the pathogenesis of Parkinson disease","volume":"111","author":"Dawson","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neulet.2005.01.024","article-title":"Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition","volume":"380","author":"Miwa","year":"2005","journal-title":"Neurosci. Lett."},{"key":"ref_133","first-page":"1464","article-title":"Chaperone-mediated autophagy markers in Parkinson disease brains","volume":"67","author":"Cooper","year":"2010","journal-title":"Arch. Neurol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.nbd.2009.05.023","article-title":"Alterations in lysosomal and proteasomal markers in Parkinson\u2019s disease: Relationship to alpha-synuclein inclusions","volume":"35","author":"Chu","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.nbd.2011.05.022","article-title":"Alteration of autophagosomal proteins (LC3, GABARAP and GATE-16) in Lewy body disease","volume":"43","author":"Tanji","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"12535","DOI":"10.1523\/JNEUROSCI.1920-10.2010","article-title":"Pathogenic lysosomal depletion in Parkinson\u2019s disease","volume":"30","author":"Dehay","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Yang, X., and Xu, Y. (2014). Mutations in the ATP13A2 gene and Parkinsonism: A preliminary review. BioMed Res. Int., 2014.","DOI":"10.1155\/2014\/371256"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/ana.20256","article-title":"PINK1 mutations are associated with sporadic early-onset parkinsonism","volume":"56","author":"Valente","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/33416","article-title":"Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism","volume":"392","author":"Kitada","year":"1998","journal-title":"Nature"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2014.12.007","article-title":"The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson\u2019s disease","volume":"85","author":"Pickrell","year":"2015","journal-title":"Neuron"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/WCO.0000000000000715","article-title":"GBA1-associated parkinsonism: New insights and therapeutic opportunities","volume":"32","author":"Ryan","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"ref_142","first-page":"25","article-title":"Apoptosis and autophagy in nigral neurons of patients with Parkinson\u2019s disease","volume":"12","author":"Anglade","year":"1997","journal-title":"Histol. Histopathol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1073\/pnas.94.14.7531","article-title":"Nuclear translocation of NF-\u03baB is increased in dopaminergic neurons of patients with Parkinson disease","volume":"94","author":"Hunot","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0304-3940(96)12961-X","article-title":"bcl-2 protein is increased in the brain from parkinsonian patients","volume":"215","author":"Mogi","year":"1996","journal-title":"Neurosci. Lett."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1073\/pnas.040556597","article-title":"Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson\u2019s disease","volume":"97","author":"Hartmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/nbdi.2002.0494","article-title":"Increased expression and redistribution of the antiapoptotic molecule Bcl-xL in Parkinson\u2019s disease","volume":"10","author":"Hartmann","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neulet.2006.12.003","article-title":"p53 protein, interferon-\u03b3, and NF-\u03baB levels are elevated in the parkinsonian brain","volume":"414","author":"Mogi","year":"2007","journal-title":"Neurosci. Lett."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1096\/fj.04-2751com","article-title":"Aggregated \u03b1-synuclein activates microglia: A process leading to disease progression in Parkinson\u2019s disease","volume":"19","author":"Zhang","year":"2005","journal-title":"FASEB J."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5607\/en.2015.24.2.103","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease","volume":"24","author":"Moon","year":"2015","journal-title":"Exp. Neurobiol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1471-4159.1990.tb02325.x","article-title":"Mitochondrial complex I deficiency in Parkinson\u2019s disease","volume":"54","author":"Schapira","year":"1990","journal-title":"J. Neurochem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ana.410320612","article-title":"Platelet mitochondria function in Parkinson\u2019s disease","volume":"32","author":"Krige","year":"1992","journal-title":"Ann. Neurol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0022-510X(91)90311-T","article-title":"Respiratory chain abnormalities in skeletal muscle from patients with Parkinson\u2019s disease","volume":"104","author":"Bindoff","year":"1991","journal-title":"J. Neurol. Sci."},{"key":"ref_153","first-page":"598","article-title":"Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine exposure","volume":"46","author":"Langston","year":"1999","journal-title":"Ann. Neurol. Off. J. Am. Neurol. Assoc. Child. Neurol. Soc."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/0024-3205(85)90146-8","article-title":"Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine","volume":"36","author":"Nicklas","year":"1985","journal-title":"Life Sci."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1074\/jbc.M710012200","article-title":"Mitochondrial import and accumulation of \u03b1-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain","volume":"283","author":"Devi","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"21490","DOI":"10.1074\/jbc.M113.545749","article-title":"Soluble, prefibrillar \u03b1-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction","volume":"289","author":"Luth","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_157","first-page":"ra342","article-title":"\u03b1-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson\u2019s disease","volume":"8","author":"Barrett","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1046\/j.1471-4159.2002.00990.x","article-title":"Protective action of the peroxisome proliferator-activated receptor-\u03b3 agonist pioglitazone in a mouse model of Parkinson\u2019s disease","volume":"82","author":"Breidert","year":"2002","journal-title":"J. Neurochem."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1046\/j.1471-4159.2003.02210.x","article-title":"Protection by pioglitazone in the MPTP model of Parkinson\u2019s disease correlates with I\u03baB\u03b1 induction and block of NF\u03baB and iNOS activation","volume":"88","author":"Dehmer","year":"2004","journal-title":"J. Neurochem."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1016\/j.bmcl.2010.06.128","article-title":"Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening","volume":"20","author":"Geldenhuys","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.expneurol.2012.08.012","article-title":"In search of the neuroprotective mechanism of thiazolidinediones in Parkinson\u2019s disease","volume":"238","author":"Ridder","year":"2012","journal-title":"Exp. Neurol."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Carta, A.R., Pisanu, A., and Carboni, E. (2011). Do PPAR-gamma agonists have a future in Parkinson\u2019s disease therapy?. Parkinson\u2019s Dis., 2011.","DOI":"10.4061\/2011\/689181"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-8-91","article-title":"The PPAR-\u03b3 agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys","volume":"8","author":"Swanson","year":"2011","journal-title":"J. Neuroinflammation"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.pharep.2018.11.005","article-title":"PPAR-\u03b3 agonist pioglitazone reduces microglial proliferation and NF-\u03baB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson\u2019s disease","volume":"71","author":"Machado","year":"2019","journal-title":"Pharmacol. Rep."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zhao, W., Li, G., Chen, J., Guan, X., Chen, X., and Guan, Z. (2017). Neuroprotective effect and mechanism of thiazolidinedione on dopaminergic neurons in vivo and in vitro in Parkinson\u2019s disease. PPAR Res., 2017.","DOI":"10.1155\/2017\/4089214"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/j.1471-4159.2006.04327.x","article-title":"Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system","volume":"100","author":"Hunter","year":"2007","journal-title":"J. Neurochem."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.neulet.2007.12.019","article-title":"Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague\u2013Dawley rats","volume":"432","author":"Hunter","year":"2008","journal-title":"Neurosci. Lett."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jneuroim.2007.09.029","article-title":"Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-\u03baB and JNK activation and suppression of COX-2 activity","volume":"192","author":"Xing","year":"2007","journal-title":"J. Neuroimmunol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-5-4","article-title":"Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K\/Akt","volume":"5","author":"Xing","year":"2008","journal-title":"J. Neuroinflamm."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.neuroscience.2011.07.046","article-title":"Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: New evidences on neuroprotection in a progressive Parkinson\u2019s disease model","volume":"194","author":"Carta","year":"2011","journal-title":"Neuroscience"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-016-0346-z","article-title":"The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson\u2019s disease: Evidence for a neuroprotective effect of rosiglitazone in the eye and brain","volume":"4","author":"Normando","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbrc.2005.11.177","article-title":"Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity","volume":"340","author":"Jung","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jns.2006.11.020","article-title":"Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production","volume":"253","author":"Jung","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"100871","DOI":"10.1016\/j.mam.2020.100871","article-title":"PPAR\u03b4 and its ligand erucic acid may act anti-tumoral, neuroprotective, and myelin protective in neuroblastoma, glioblastoma, and Parkinson\u2019s disease","volume":"78","author":"Altinoz","year":"2021","journal-title":"Mol. Asp. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2174\/1567202611666140318114037","article-title":"A PPAR-\u03b2\/\u03b4 agonist is neuroprotective and decreases cognitive impairment in a rodent model of Parkinson\u2019s disease","volume":"11","author":"Das","year":"2014","journal-title":"Curr. Neurovasc. Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12017-020-08629-9","article-title":"Recent Insights on the Role of PPAR-\u03b2\/\u03b4 in Neuroinflammation and Neurodegeneration, and Its Potential Target for Therapy","volume":"23","author":"Strosznajder","year":"2021","journal-title":"NeuroMol. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.brainres.2006.12.011","article-title":"Lipid-lowering drugs in the MPTP mouse model of Parkinson\u2019s disease: Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not","volume":"1135","author":"Kreisler","year":"2007","journal-title":"Brain Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pnpbp.2014.02.009","article-title":"PPAR-\u03b1 agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson\u2019s disease","volume":"53","author":"Barbiero","year":"2014","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainres.2018.09.036","article-title":"Neuroprotective effects of MHY908, a PPAR \u03b1\/\u03b3 dual agonist, in a MPTP-induced Parkinson\u2019s disease model","volume":"1704","author":"Lee","year":"2019","journal-title":"Brain Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0304-3940(00)01294-5","article-title":"Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro","volume":"289","author":"Casper","year":"2000","journal-title":"Neurosci. Lett."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10787-020-00764-w","article-title":"Neuroinflammatory responses in Parkinson\u2019s disease: Relevance of Ibuprofen in therapeutics","volume":"29","author":"Singh","year":"2021","journal-title":"Inflammopharmacology"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s11481-020-09925-8","article-title":"Combined 1-deoxynojirimycin and ibuprofen treatment decreases Microglial activation, phagocytosis and dopaminergic degeneration in MPTP-treated mice","volume":"16","author":"Costa","year":"2021","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Won, S., Ko, J.H., Jeon, H., Park, S.-S., and Kim, S.-N. (2021). Co-Administration of Gagam-Sipjeondaebo-Tang and Ibuprofen Alleviates the Inflammatory Response in MPTP-Induced Parkinson\u2019s Disease Mouse Model and RAW264. 7 Macrophages. Pathogens, 10.","DOI":"10.3390\/pathogens10030268"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1567-5769(02)00078-4","article-title":"Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice","volume":"2","author":"Babiuch","year":"2002","journal-title":"Int. Immunopharmacol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"108378","DOI":"10.1016\/j.neuropharm.2020.108378","article-title":"Celecoxib promotes survival and upregulates the expression of neuroprotective marker genes in two different in vitro models of Parkinson\u2019s disease","volume":"194","author":"Dassati","year":"2021","journal-title":"Neuropharmacology"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/WNR.0000000000000740","article-title":"Montelukast treatment protects nigral dopaminergic neurons against microglial activation in the 6-hydroxydopamine mouse model of Parkinson\u2019s disease","volume":"28","author":"Jang","year":"2017","journal-title":"Neuroreport"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neulet.2018.05.052","article-title":"Effect of montelukast in experimental model of Parkinson\u2019s disease","volume":"682","author":"Nagarajan","year":"2018","journal-title":"Neurosci. Lett."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.taap.2018.09.012","article-title":"Montelukast attenuates rotenone-induced microglial activation\/p38 MAPK expression in rats: Possible role of its antioxidant, anti-inflammatory and antiapoptotic effects","volume":"358","author":"Mansour","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2006.09.024","article-title":"Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators","volume":"127","author":"Drori","year":"2006","journal-title":"Cell"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/ncpneuro0586","article-title":"Drug insight: Effects mediated by peroxisome proliferator-activated receptor-\u03b3 in CNS disorders","volume":"3","author":"Heneka","year":"2007","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1073\/pnas.0503839103","article-title":"Nonsteroidal anti-inflammatory drugs repress \u03b2-secretase gene promoter activity by the activation of PPAR\u03b3","volume":"103","author":"Sastre","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.expneurol.2007.02.008","article-title":"Non-steroidal anti-inflammatory drugs in Parkinson\u2019s disease","volume":"205","author":"Esposito","year":"2007","journal-title":"Exp. Neurol."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Wallin, J., and Svenningsson, P. (2021). Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson\u2019s Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115606"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1016\/j.clnu.2021.05.011","article-title":"Effect of dietary vitamins C and E on the risk of Parkinson\u2019s disease: A meta-analysis","volume":"40","author":"Chang","year":"2021","journal-title":"Clin. Nutr."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Makkar, R., Behl, T., Bungau, S., Zengin, G., Mehta, V., Kumar, A., Uddin, M.S., Ashraf, G.M., Abdel-Daim, M.M., and Arora, S. (2020). Nutraceuticals in Neurological Disorders. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124424"},{"key":"ref_196","first-page":"1452696","article-title":"PGC-1\u03b1, inflammation, and oxidative stress: An integrative view in metabolism","volume":"2020","author":"Ortega","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Piccinin, E., Sardanelli, A.M., Seibel, P., Moschetta, A., Cocco, T., and Villani, G. (2021). PGC-1s in the Spotlight with Parkinson\u2019s Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073487"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"52ra73","DOI":"10.1126\/scitranslmed.3001059","article-title":"PGC-1\u03b1, a potential therapeutic target for early intervention in Parkinson\u2019s disease","volume":"2","author":"Zheng","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.neulet.2010.02.034","article-title":"Reduced expression of peroxisome-proliferator activated receptor gamma coactivator-1\u03b1 enhances \u03b1-synuclein oligomerization and down regulates AKT\/GSK3\u03b2 signaling pathway in human neuronal cells that inducibly express \u03b1-synuclein","volume":"473","author":"Ebrahim","year":"2010","journal-title":"Neurosci. Lett."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cell.2011.02.010","article-title":"PARIS (ZNF746) repression of PGC-1\u03b1 contributes to neurodegeneration in Parkinson\u2019s disease","volume":"144","author":"Shin","year":"2011","journal-title":"Cell"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1523\/JNEUROSCI.4441-10.2011","article-title":"Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells","volume":"31","author":"Seibler","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00018-011-0850-z","article-title":"Transgenic expression and activation of PGC-1\u03b1 protect dopaminergic neurons in the MPTP mouse model of Parkinson\u2019s disease","volume":"69","author":"Mudo","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nature05292","article-title":"Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases","volume":"443","author":"Lin","year":"2006","journal-title":"Nature"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/oxfordjournals.aje.a116960","article-title":"Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson\u2019s disease","volume":"139","author":"Grandinetti","year":"1994","journal-title":"Am. J. Epidemiol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.10028","article-title":"Cigarette smoking and the incidence of Parkinson\u2019s disease in two prospective studies","volume":"50","author":"Zhang","year":"2001","journal-title":"Ann. Neurol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000054770","article-title":"Risk factors for Parkinson\u2019s disease: The leisure world cohort study","volume":"20","year":"2001","journal-title":"Neuroepidemiology"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.10277","article-title":"A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson\u2019s disease","volume":"52","author":"Takkouche","year":"2002","journal-title":"Ann. Neurol."},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"Breckenridge, C.B., Berry, C., Chang, E.T., Sielken Jr, R.L., and Mandel, J.S. (2016). Association between Parkinson\u2019s disease and cigarette smoking, rural living, well-water consumption, farming and pesticide use: Systematic review and meta-analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151841"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/archneur.64.7.990","article-title":"Pooled analysis of tobacco use and risk of Parkinson disease","volume":"64","author":"Ritz","year":"2007","journal-title":"Arch. Neurol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.45.6.1041","article-title":"Cigarette smoking and protection from Parkinson\u2019s disease: False association or etiologic clue?","volume":"45","author":"Morens","year":"1995","journal-title":"Neurology"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.tins.2004.06.008","article-title":"Smoking, nicotine and Parkinson\u2019s disease","volume":"27","author":"Quik","year":"2004","journal-title":"Trends Neurosci."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.bbapap.2008.09.026","article-title":"Smoking and Parkinson\u2019s disease: Does nicotine affect \u03b1-synuclein fibrillation?","volume":"1794","author":"Hong","year":"2009","journal-title":"Biochim. Biophys. Acta Proteins Proteom."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1212\/WNL.0000000000000879","article-title":"Parkinson disease and smoking revisited: Ease of quitting is an early sign of the disease","volume":"83","author":"Ritz","year":"2014","journal-title":"Neurology"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1212\/WNL.0000000000004898","article-title":"Caffeine and Parkinson disease: A possible diagnostic and pathogenic breakthrough","volume":"90","author":"Munoz","year":"2018","journal-title":"Neurology"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3389\/fnins.2020.602697","article-title":"Caffeine and Parkinson\u2019s Disease: Multiple Benefits and Emerging Mechanisms","volume":"14","author":"Ren","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Hong, C.T., Chan, L., and Bai, C.-H. (2020). The effect of caffeine on the risk and progression of Parkinson\u2019s disease: A meta-analysis. Nutrients, 12.","DOI":"10.3390\/nu12061860"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1001\/jama.283.20.2674","article-title":"Association of coffee and caffeine intake with the risk of Parkinson disease","volume":"283","author":"Ross","year":"2000","journal-title":"JAMA"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"RC143","DOI":"10.1523\/JNEUROSCI.21-10-j0001.2001","article-title":"Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson\u2019s disease","volume":"21","author":"Chen","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_219","first-page":"56","article-title":"Prospective study of caffeine consumption and risk of Parkinson\u2019s disease in men and women","volume":"50","author":"Ascherio","year":"2001","journal-title":"Ann. Neurol. Off. J. Am. Neurol. Assoc. Child. Neurol. Soc."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/WNL.55.9.1350","article-title":"Smoking, alcohol, and coffee consumption preceding Parkinson\u2019s disease: A case-control study","volume":"55","author":"Benedetti","year":"2000","journal-title":"Neurology"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1523\/JNEUROSCI.3008-05.2006","article-title":"Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson\u2019s disease","volume":"26","author":"Xu","year":"2006","journal-title":"J. Neurosci."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s00415-018-9032-3","article-title":"Alcohol consumption and risk for Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"266","year":"2019","journal-title":"J. Neurol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/mds.25863","article-title":"Alcohol intake and risk of Parkinson\u2019s disease: A meta-analysis of observational studies","volume":"29","author":"Zhang","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Peng, B., Yang, Q., Joshi, R.B., Liu, Y., Akbar, M., Song, B.J., Zhou, S., and Wang, X. (2020). Role of Alcohol Drinking in Alzheimer\u2019s Disease, Parkinson\u2019s Disease, and Amyotrophic Lateral Sclerosis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072316"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S1353-8020(13)70030-0","article-title":"Exercise: Is it a neuroprotective and if so, how does it work?","volume":"20","author":"Zigmond","year":"2014","journal-title":"Parkinsonism Relat Disord."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.neuroscience.2006.03.027","article-title":"Enriched environment improves motor function in intact and unilateral dopamine-depleted rats","volume":"140","author":"Jadavji","year":"2006","journal-title":"Neuroscience"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/B:MEBR.0000027416.13070.c3","article-title":"Voluntary running provides neuroprotection in rats after 6-hydroxydopamine injection into the medial forebrain bundle","volume":"19","author":"Mabandla","year":"2004","journal-title":"Metab. Brain Dis."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.neuroscience.2006.10.042","article-title":"Running wheel exercise enhances recovery from nigrostriatal dopamine injury without inducing neuroprotection","volume":"144","author":"Gross","year":"2007","journal-title":"Neuroscience"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.expneurol.2005.11.004","article-title":"Enriched environment induces cellular plasticity in the adult substantia nigra and improves motor behavior function in the 6-OHDA rat model of Parkinson\u2019s disease","volume":"199","author":"Steiner","year":"2006","journal-title":"Exp. Neurol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/jnr.20162","article-title":"Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia","volume":"77","author":"Fisher","year":"2004","journal-title":"J. Neurosci. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/18\/10161\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:02:48Z","timestamp":1760166168000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/18\/10161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":230,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["ijms221810161"],"URL":"https:\/\/doi.org\/10.3390\/ijms221810161","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,21]]}}}